Metoclopramide Baxter (Metoclopramide Hydrochloride Anhydrous)

Metoclopramide works by blocking dopamine D2 receptors in the chemoreceptor trigger zone, which reduces the vomiting reflex. It also antagonizes serotonin 5‑HT3 receptors and stimulates 5‑HT4 receptors, actions that increase the tone and coordinated contractions of the upper gastrointestinal tract, thereby promoting gastric emptying.

The specific dose and duration of Metoclopramide therapy are determined by the prescribing clinician based on the patient’s condition, age, renal function and response to treatment. Healthcare professionals follow local prescribing guidelines and adjust the regimen as needed for safety and efficacy.

Safety data for Metoclopramide during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician after evaluating the clinical situation.

To place an order, submit an enquiry on the Metoclopramide Baxter product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and any required import documentation.

Metoclopramide differs from many antiemetics by combining dopamine antagonism with serotonergic activity and a pro‑kinetic effect on the gastrointestinal tract. Unlike pure 5‑HT3 antagonists such as ondansetron, it also enhances gastric motility, making it useful in conditions like gastroparesis, but it carries a higher risk of extrapyramidal side effects.

Metoclopramide Baxter should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the product, and keep it in the original packaging until use. Before administration, allow the solution to reach room temperature if required by the clinical protocol.

Metoclopramide Baxter is supplied for intramuscular or intravenous injection. The route, rate of infusion and dilution are determined by the prescriber and nursing staff according to the clinical indication, patient condition and institutional guidelines.

Serious adverse reactions include tardive dyskinesia, neuroleptic malignant syndrome, severe depression or suicidal thoughts, seizures, anaphylactic reactions and cardiac arrhythmias. Patients should be monitored for any new movement disorders, mood changes or signs of severe hypersensitivity, and the drug should be discontinued immediately if these occur.

Metoclopramide is contraindicated in individuals with known hypersensitivity to the drug, in patients with pheochromocytoma, and in those with a history of severe extrapyramidal reactions. Caution is also advised for patients with gastrointestinal obstruction, perforation, or severe renal impairment, where alternative therapies should be considered.